The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.

The present invention discloses solvent free process for extracting cholesterol free of impurities from milk fat. The so isolated cholesterol is useful for the further preparation of vitamin D3. The present invention further provides pharmaceutical grade cholesterol from milk fat of high purity.

The present disclosure relates to a continuous process for melt-coating active pharmaceutical ingredients, including introducing at least one active pharmaceutical ingredient (API) and at least one surfactant into a processor; and continuously and simultaneously heating and shearing the API and surfactant in the processor at a temperature close to the melting point of the surfactant so as to continuously form melt-coated API particles having at least a partial coating of surfactant. The disclosure also relates to melt-coated API particles prepared by the disclosed continuous melt-coating process, and pharmaceutical drug products prepared from such melt-coated API particles.

The present disclosure relates to a continuous process for melt-coating active pharmaceutical ingredients, including introducing at least one active pharmaceutical ingredient (API) and at least one surfactant into a processor; and continuously and simultaneously heating and shearing the API and surfactant in the processor at a temperature close to the melting point of the surfactant so as to continuously form melt-coated API particles having at least a partial coating of surfactant. The disclosure also relates to melt-coated API particles prepared by the disclosed continuous melt-coating process, and pharmaceutical drug products prepared from such melt-coated API particles.

Disclosed herein are antiviral compositions for treating CoV. In some embodiments, the antiviral compositions include at least 5 components selected from: a therapeutically effect amount of spikenard or an extract thereof; a therapeutically effective amount of at least one mineral; a therapeutically effective amount of at least one vitamin; a therapeutically effective amount of oregano oil or at least one active component included within oregano oil; a therapeutically effective amount of one or more Artemisinins or derivatives or analogs thereof; a therapeutically effective amount of one or more Salvia species or an extract thereof; and a therapeutically effective amount of cardamom oil or an extract thereof.

Disclosed herein are antiviral compositions for treating CoV. In some embodiments, the antiviral compositions include at least 5 components selected from: a therapeutically effect amount of spikenard or an extract thereof; a therapeutically effective amount of at least one mineral; a therapeutically effective amount of at least one vitamin; a therapeutically effective amount of oregano oil or at least one active component included within oregano oil; a therapeutically effective amount of one or more Artemisinins or derivatives or analogs thereof; a therapeutically effective amount of one or more Salvia species or an extract thereof; and a therapeutically effective amount of cardamom oil or an extract thereof.

Disclosed herein are antiviral compositions for treating CoV. In some embodiments, the antiviral compositions include at least 5 components selected from: a therapeutically effect amount of spikenard or an extract thereof; a therapeutically effective amount of at least one mineral; a therapeutically effective amount of at least one vitamin; a therapeutically effective amount of oregano oil or at least one active component included within oregano oil; a therapeutically effective amount of one or more Artemisinins or derivatives or analogs thereof; a therapeutically effective amount of one or more Salvia species or an extract thereof; and a therapeutically effective amount of cardamom oil or an extract thereof.

The present invention provides a composition and method of treating infection-induced cardiomyopathy in a subject, the method comprising administering to the subject a therapeutically effective amount of a nitrogen-containing bisphosphonate or a pharmaceutically effective salt thereof, wherein the nitrogen-containing bisphosphonate is useful as a therapeutic agent, in particular in the treatment, therapy or prophylaxis of the novel coronavirus COVID-19.